Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Jedd D. Wolchok, Paolo A. Ascierto, F. Stephen Hodi, Alexander M.M. Eggermont, Omid Hamid, Caroline Robert, Adil Daud, Tara C. Gangadhar, Scot Ebbinghaus, Xiaoyun Li, Sunyu Kang, Antoni Ribas, Christian U. Blank, Jeffrey A. Sosman, René González, Dirk Schadendorf, Reinhard Dummer, Matteo S. Carlino, Igor Puzanov, Jacob Schachter, Kim Margolin, John M. Kirkwood, Thomas Eigentler, Sanjiv S. Agarwala, Wei Zhou, Steven O’Day, Carmen Loquai, Ronnie Shapira‐Frommer, April K.S. Salama, Anna C. Pavlick, Stergios J. Moschos, Karl D. Lewis, Lee D. Cranmer, Simone M. Goldinger, Adriane M Zernhelt, Joy Lis

2015-06-24

SCID: 54.1/zukbedtn

Publication Details

DOI

10.1016/s1470-2045(15)00083-2

Publication Date

2015-06-24

Journal

Publisher

ISSN

Access Type

Author Information

Authors

Jedd D. Wolchok

Paolo A. Ascierto

F. Stephen Hodi

Alexander M.M. Eggermont

Omid Hamid

Caroline Robert

Adil Daud

Tara C. Gangadhar

Scot Ebbinghaus

Xiaoyun Li

Sunyu Kang

Antoni Ribas

Christian U. Blank

Jeffrey A. Sosman

René González

Dirk Schadendorf

Reinhard Dummer

Matteo S. Carlino

Igor Puzanov

Jacob Schachter

Kim Margolin

John M. Kirkwood

Thomas Eigentler

Sanjiv S. Agarwala

Wei Zhou

Steven O’Day

Carmen Loquai

Ronnie Shapira‐Frommer

April K.S. Salama

Anna C. Pavlick

Stergios J. Moschos

Karl D. Lewis

Lee D. Cranmer

Simone M. Goldinger

Adriane M Zernhelt

Joy Lis

Download PDF